Summary of Biofrontera (BFRI) Q2 2026 Earnings Call

1Key Financial Results and Metrics

Net Product Revenue: $12 million, up 33% year-over-year (Q2 2025: $9 million).

Gross Margin: Approximately 80%, an increase from 71% in the prior year.

Adjusted EBITDA: Breakeven at $200,000, a significant improvement from a loss of $5.1 million in Q2 2025.

Net Loss: $0.6 million ($0.05 per share), improved from a loss of $5.3 million ($0.57 per share) in Q2 2025.

Cash Position: $4.7 million as of June 30, 2026, down from $6.4 million at year-end 2025. Operating cash used in the first half was $1.7 million, a reduction from $7.2 million a year ago.

2Strategic Updates and Business Highlights

Strong Performance: The second quarter was noted as the strongest Q2 and H1 in the company's history as a standalone U.S. business.

Ameluz Sales Growth: Unit volume increased by approximately 30%, with 33,300 tubes sold in Q2 2026 compared to 25,300 in Q2 2025.

Clinical Pipeline:

FDA accepted a supplemental NDA for Ameluz PDT for superficial basal cell carcinoma (sBCC) with a PDUFA date of September 28, 2026.

Positive Phase III results for actinic keratosis (AK) label expansion expected to file by Q3 2026.

Ongoing development for moderate to severe acne treatment.

Commercial Strategy: Continued focus on expanding the installed base of BF-RhodoLED lamps and increasing customer engagement.

3Forward Guidance and Outlook

Revenue Goals: The company expects to meet its full-year 2026 revenue goals despite the ITC-related restrictions.

Growth Projections: Anticipated launches for sBCC in Q1 2027 and AK label expansion in Q3 2027, leveraging existing commercial infrastructure.

4Bad News, Challenges, or Points of Concern

ITC Ruling: The International Trade Commission issued a ruling that restricts the sale of the RhodoLED XL lamp and Ameluz for use with it. The company is pursuing an appeal but is also implementing a remediation plan to modify the lamp.

Cash Flow Concerns: The company has a going concern qualification in its financial statements, indicating potential liquidity issues. Continued growth in Ameluz revenue is critical for maintaining operations.

Dependence on FDA Approval: Future revenue growth is contingent on successful FDA approvals for new indications and modifications to existing products.

5Notable Q&A Insights

Basal Cell Carcinoma Launch Preparation: The company is finalizing marketing materials and training the sales force for the upcoming launch of sBCC.

ITC Patent Challenges: Biofrontera cannot challenge the second patent through the same mechanism as the first but will appeal the ITC's decision. The remediation plan involves minor design changes to the lamp, which will require FDA approval.

Customer Usage of Ameluz: Customers with the infringing XL lamp can still use Ameluz purchased before the ITC ruling, but Biofrontera cannot encourage future sales for that device.

Replacement Strategy: Once the non-infringing lamp is approved, Biofrontera plans to work with customers to replace their current lamps. Overall, Biofrontera demonstrated strong operational performance in Q2 2026, with significant revenue growth and improved margins, while navigating challenges related to regulatory restrictions and cash flow management. The company remains focused on expanding its product offerings and addressing legal hurdles to sustain growth.